20 February 2025

ProBiotix Health plc

("ProBiotix" or the "Company" or, together with its subsidiary, the "Group")

Grant of Options

ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, announces that options ("Options") have been granted over a total of 9,050,000 ordinary shares of 0.05p each in the Company ("Ordinary Shares") to Steen Andersen, Chief Executive of ProBiotix, and certain other key employees of the Company.

The options were granted on 19 February 2025 with an exercise price of 9.5p per share. The Options may be exercised within 10 years from the date of their grant, subject to satisfaction of commercially oriented performance criteria, which includes significant revenue targets.

Option holders can only exercise Options once these conditions have been met. This ensures a continued focus on commercial revenues and shareholder value creation.

For further information, please contact:

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

Notes to Editors:

ProBiotix is a life sciences company that develops probiotic formulations to support cardiometabolic health. Since its formation, ProBiotix has become recognised as a global leader in microbiome modulating probiotics for use in food supplements and nutraceuticals.

The Company has a unique approach; discovering ground breaking probiotics, ensuring their benefits through robust science, and bringing to market effective finished probiotic-based products for human health across the globe.